Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.10)
# 512
Out of 5,122 analysts
231
Total ratings
61.88%
Success rate
8.81%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UNH UnitedHealth Group | Maintains: Overweight | $411 → $409 | $275.92 | +48.23% | 21 | Jan 23, 2026 | |
| DOCS Doximity | Upgrades: Overweight | $62 → $65 | $35.25 | +84.40% | 11 | Dec 15, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $201.62 | -8.24% | 23 | Nov 11, 2025 | |
| CNC Centene | Maintains: Equal-Weight | $28 → $38 | $40.96 | -7.23% | 14 | Oct 14, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $276.16 | +10.81% | 17 | Jul 25, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $6.93 | +44.30% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.21 | +148.87% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $13.22 | -43.27% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $21.33 | -43.74% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $189.23 | -23.37% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $178.04 | +105.01% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $822.00 | -48.91% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $4.40 | +2,627.27% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $192.07 | +222.80% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $340.60 | +46.80% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $75.24 | +64.81% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $271.71 | +17.04% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $206.85 | -66.16% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $202.54 | -3.72% | 6 | Oct 21, 2020 |
UnitedHealth Group
Jan 23, 2026
Maintains: Overweight
Price Target: $411 → $409
Current: $275.92
Upside: +48.23%
Doximity
Dec 15, 2025
Upgrades: Overweight
Price Target: $62 → $65
Current: $35.25
Upside: +84.40%
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $201.62
Upside: -8.24%
Centene
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $28 → $38
Current: $40.96
Upside: -7.23%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $276.16
Upside: +10.81%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $6.93
Upside: +44.30%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.21
Upside: +148.87%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $13.22
Upside: -43.27%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $21.33
Upside: -43.74%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $189.23
Upside: -23.37%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $178.04
Upside: +105.01%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $822.00
Upside: -48.91%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $4.40
Upside: +2,627.27%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $192.07
Upside: +222.80%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $340.60
Upside: +46.80%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $75.24
Upside: +64.81%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $271.71
Upside: +17.04%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $206.85
Upside: -66.16%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $202.54
Upside: -3.72%